Proprietary Rivastigmine Nasal Spray
Our proprietary Rivastigmine Nasal Spray has the potential to improve the efficacy, tolerability and convenience of this class of drugs known as cholinesterase inhibitors.
We conducted the first human study of nasal absorption of a cholinesterase inhibitor (rivastigmine) and it confirmed the nasal spray could provide a therapeutically effective level.
ANZCTR reference: ACTRN12614001313628
Morgan TM, Soh B. Absolute Bioavailability and Safety of a Novel Rivastigmine Nasal Spray in Healthy Elderly Individuals. Br J Clin Pharmacol. 2017 83(3):510-516 PMID: 27639640 DOI: 10.1111/bcp.13133
We are also developing nasal sprays with sigma-one agonists and NMDA antagonists alone, or in combination, with rivastigmine.
In vitro diffusion studies across freshly excised, Bovine nasal mucosa has proven to be a reasonable way for us to evaluate new drug candidates in our proprietary nasal formulations.